CTO-PCI Technology for Heart Health in Egypt

By Melike Belenli Gümüş

October 24, 2024

The article from the Egypt Healthcare Authority (EHA) discusses the successful implementation and benefits of using CTO-PCI (Chronic Total Occlusion Percutaneous Coronary Intervention) technology to treat chronic coronary artery occlusion in Egypt. Here are some key points to consider:

  • Success of Procedures: The EHA reported the successful treatment of three elderly patients (all over 60 years old) using CTO-PCI technology with micro-catheters and specialised wires at the International Medical Complex in Luxor. The procedures achieved a 100% success rate.
  • Cost and Universal Health Coverage: The cost of CTO-PCI procedures outside the universal health coverage system exceeds 500,000 Egyptian pounds. However, under the universal health insurance system, patients contribute no more than 400 EGP.
  • Medical Team and Expertise: The procedures were conducted by a highly skilled team of medical consultants, including top professors, cardiologists, and specialised nursing and technical staff. Key team members included Dr. Tarek Rashid, Head of the Scientific Committee for Cardiology, and Dr. Zein El-Abidin Abdel-Latif, Head of the Cardiology and Catheterization Department.
  • Commitment to Innovation: The EHA emphasised its commitment to innovation and continuous development, adopting the latest global medical advances and introducing cutting-edge technologies across all medical specialties, particularly in cardiology.
  • Patient Benefits: The patients treated were suffering from angina and severe pain due to coronary artery occlusion. The use of CTO-PCI technology significantly improved their quality of life.
  • Healthcare Model: The EHA aims to provide a modern healthcare model in Egypt by ensuring access to the latest global medical advancements and maintaining a team of expert consultants.

This initiative reflects the Authority‘s dedication to providing innovative medical technologies and achieving high-quality care for patients under the universal health insurance system.

Reference url

Recent Posts

Substandard Medicines in South Africa: Regulatory Challenges and Economic Implications

By HEOR Staff Writer

May 21, 2026

Substandard medicines in South Africa continue to infiltrate supply chains through informal markets, unlicensed outlets, and online platforms, leaving patients exposed to unregulated weight-loss injections amid stock shortages and high costs for approved options such as Ozempic. Comp...
First-in-Human Trials: Foundations and Market Implications in Health Economics
First-in-Human Trials mark the initial transition of a drug candidate from extensive preclinical research into human subjects, supplying the earliest clinical evidence on safety, pharmacokinetics, and pharmacodynamics to inform later development stages. These studies rely on a comprehensive found...
Transforming Healthcare Value: Strategic Purchasing in South Africa

By João L. Carapinha

May 20, 2026

Strategic Purchasing Healthcare offers a pathway for South Africa’s healthcare system to deliver improved patient outcomes amid constrained resources, where traditional passive purchasing models relying on historical budgets or uncapped fee-for-service payments have fallen short in prioritising e...